Русский
Possibilities of the combination of avelumab and axitinib in the first line in patients with advanced renal cell carcinoma
DOI: https://dx.doi.org/10.18565/pharmateca.2022.11-12.99-105
A.I. Semenova, S.A. Protsenko, G.M. Teletaeva, D.Kh. Latipova, A.V. Novik
1) N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; 2) St. Petersburg State Pediatric Medical University, St. Petersburg, Russia
Combination regimens based on immune checkpoint inhibitors demonstrate a significant advantage in the first line for metastatic kidney cancer. The results of the phase III randomized JAVELIN Renal 101 trial confirm the possibility of a significant improvement in progres- sion-free survival and an increase in the objective response rate when prescribing the combination of avelumab and axitinib compared with sunitinib therapy in all subgroups of patients, regardless of the PD-L1 expression level and prognostic risk group. In the subgroup of patients with sarcomatoid component of kidney cancer who have the most unfavorable prognosis, the combination of avelumab and axitinib also provides improved efficacy compared with sunitinib.
Keywords: immune checkpoint blockers, axitinib, avelumab, sarcomatoid variant of renal cell carcinoma, renal cell carcinoma, clinical trials
About the Autors
Corresponding author: Anna I. Semenova, Cand. Sci. (Med.), Senior Researcher Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, Oncologist at the Department of Antitumor Drug Therapy, Associate Professor at the Department of Additional Professional Education, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; St. Petersburg, Russia; mirannia@yandex.ru; https://orcid.org/0000- 0003-4538-8646
Similar Articles
